Medincell Stock Consolidates at -2% After a May Boosted by Announcements
The biotech company based in Montpellier continues its decline at midday, in a Parisian market that is also trending downward. This movement occurs as a broker has just raised its price target, reigniting the debate between fundamental momentum and the ongoing technical consolidation.
Portzamparc Raises Target to €30 and Reaffirms Buy Recommendation
On June 3, Portzamparc raised its price target on Medincell from €29.20 to €30.00, while reaffirming its buy recommendation. Based on a price of €26.24, the new target offers a theoretical potential of about 14%. This revision follows a series of significant news for the biotech: the acceptance of the Olanzapine LAI dossier by the EMA on May 22, in partnership with Teva, and the announcement on May 27 of participation in two American biotech conferences in June. Analysts' opinions remain positive, as the stock maintains a 60.2% increase over one year.
The Stock Falls Below its 20-Day Moving Average but Maintains Medium-Term Support
At €26.24, the price has fallen below the 20-day moving average (€27.15), a negative gap of 3.35%, indicating that the short-term momentum is waning after surpassing the resistance at €28.72 at the end of May. However, the stock remains above the 50-day moving average at €24.80 (+5.81%) and the 200-day moving average at €25.35 (+3.51%), which keeps the underlying trend intact. The RSI at 53 reflects this pause without extreme signals, in an SBF 120 that is down 0.37% during the session. The next graphical level to watch remains the support at €22.86, a level that marks the consolidation begun since the peak in May.
